ALEBUND-B
0963718AListed醫療健康 · 一家专注于肾脏疾病治疗的生物制药公司，核心产品为治疗高磷血症的AP301。
High attention
80.1
/100
- Offer price
- HK$22.60
- Final offer price
- HK$22.60
- Lot / entry fee
- 100 shares · HK$2K
- Proceeds
- HK$1.28B
- Sponsor
- Jefferies / Huatai Financial / CLSA / BOCI
- Est. margin oversub.
- 403.8x
- Public oversub.
- 963.6x
- One-lot win rate
- 6.0%
- First-day return
- +103.5%
Offer starts
Jun 18
Offer closes
Jun 24
Grey market
Jun 26
Listing
Jun 29
AI reference scoring and scenarios
After grey market
After grey market L1 heat score
80.1/ 100
Data coverage High
Target
Historical calibration
Listing-day trend
Strong positivePartial basis
Up probability
98.0%
First-day reference range
+70.9% – +157.9%
Published outcome check
First-day resultBig up+103.5%Strong all day
Our call: Trend call valid
Covered 21/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Weaker qualityCornerstone lockup
Strong supportPost-lockup offer value
Medium scarcityRecent same-rule trend
Strong trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Average appealFundamental quality
Average qualityGrowth quality
High qualityProfitability
Weak qualityCash runway
High qualityCustomer concentration
High riskCornerstone quality
Strong supportSponsor record
Strong recordGreenshoe arrangementGreenshoe: yes · 15%
Average supportStabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
Good heatInternational placing
High heatFinal pricing position
—Actual greenshoe useCumulative use 0.0%
Good supportGrey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
After grey marketThe analysis report for this IPO is being generated.